Evaluating the Content Validity, Clarity, and Relevance of Two Patient-Reported Outcomes for Use With Adults With
Epidermal growth factor receptor
Exon 20 insertion mutation
Non-small cell lung cancer
Patient-reported outcomes
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
16
04
2021
revised:
20
05
2021
accepted:
07
06
2021
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
10
2021
Statut:
epublish
Résumé
NSCLCs account for most lung cancers; approximately 30% involve a mutation in the Patients with NSCLC from the United States, Europe, and Asia and including those with an exon 20 insertion mutation and other A total of 30 individuals participated (mean age = 57 years, 87% female, 80% white). The most often reported symptoms included fatigue, shortness of breath, cough, and weight loss. Individuals with the exon 20 insertion mutation (n = 21) more frequently reported negative impacts on daily life, physical functioning, and social functioning but less frequently reported negative impacts to emotional functioning. The PROMIS Short-Form version 2.0-Physical Function 8c and the NSCLC Symptom Assessment Questionnaire were deemed clear, relevant, and easy to complete. The concepts identified during the concept elicitation portion of the interviews were mapped to the content of each PRO, and all items within both PROs were endorsed by at least 20% of the participants. These results support the content validity, clarity, and relevance of the PROMIS Short-Form version 2.0-Physical Function 8c and the NSCLC Symptom Assessment Questionnaire in a population with
Identifiants
pubmed: 34590043
doi: 10.1016/j.jtocrr.2021.100198
pii: S2666-3643(21)00057-6
pmc: PMC8474204
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100198Informations de copyright
© 2021 The Authors.
Références
Value Health. 2018 Jul;21(7):839-842
pubmed: 30005756
Cancer Discov. 2021 Jul;11(7):1688-1699
pubmed: 33632775
J Thorac Dis. 2019 Mar;11(Suppl 4):S509-S514
pubmed: 31032069
Eur Respir J. 2016 May;47(5):1502-9
pubmed: 27030679
J Clin Oncol. 2009 Dec 1;27(34):5816-22
pubmed: 19858383
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
Chest. 2002 Aug;122(2):584-9
pubmed: 12171836
Ann Thorac Med. 2018 Apr-Jun;13(2):101-107
pubmed: 29675061
J Clin Oncol. 2008 Jan 10;26(2):233-41
pubmed: 18086802
Mol Cancer Ther. 2013 Feb;12(2):220-9
pubmed: 23371856
Br J Cancer. 2008 Dec 2;99(11):1757-62
pubmed: 18985035
Patient Relat Outcome Meas. 2020 Feb 13;11:49-66
pubmed: 32104126
Clin Ther. 2016 Apr;38(4):794-810
pubmed: 27041408
Am Soc Clin Oncol Educ Book. 2016;35:67-73
pubmed: 27249687
J Clin Epidemiol. 2010 Nov;63(11):1179-94
pubmed: 20685078
Eur Respir J. 2017 Mar 29;49(3):
pubmed: 28356370
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
PLoS One. 2021 Mar 8;16(3):e0247620
pubmed: 33684140
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Lung Cancer. 2017 Nov;113:140-151
pubmed: 29110842
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2013 Feb;8(2):179-84
pubmed: 23328547
J Thorac Oncol. 2008 Jun;3(6):604-8
pubmed: 18520798
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Cancer. 2005 Nov 1;104(9):2013-21
pubmed: 16178002
Chest. 1998 Feb;113(2):467-81
pubmed: 9498968